Ascendis Pharma A/s (NASDAQ: ASND)
Ascendis Pharma A/s Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ascendis Pharma A/s Company Info
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
News & Analysis
Why Ascendis Pharma Stock Tumbled by 11% Today
A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.
Why Shares of Ascendis Pharma Are Climbing Monday
A critical response letter from the FDA means hope remains for the company's hypoparathyroidism therapy candidate.
Why Ascendis Pharma Stock Is Crashing This Week
The FDA put a roadblock in the path to market for Ascendis' hypoparathyroidism drug.
Why Ascendis Pharma Stock Is Plunging Today
A regulatory hiccup is weighing on the biopharma's shares today.
Why Ascendis Pharma Stock Is Sinking Today
Investors are reacting negatively to the company's Q1 update.
Why Shares of Ascendis Soared This Week
The pharmaceutical company saw its shares jump more than $26.
Here's Why Ascendis Pharma Shares Are Surging Higher Today
Approval of the company's weekly growth hormone is making investors smile today.
These 2 Stocks Soared Double Digits After Hours
Find out where the big winners were late Wednesday.
Valuation
Earnings Transcripts
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
ASND earnings call for the period ending September 30, 2021.
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
ASND earnings call for the period ending June 30, 2021.
Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript
ASND earnings call for the period ending March 31, 2021.
Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript
ASND earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.